Non-small cell lung cancer Trials in Guangzhou, China
Conditions / Non-small cell lung cancer / Guangzhou, China
Non-small cell lung cancer has been the subject of sustained clinical investigation across multiple research sites.
294 total trials for this combination
Showing top 10 of 294 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05899608 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | RECRUITING | — |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | TERMINATED | PHASE3 |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | RECRUITING | PHASE1/PHASE2 |
| NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | RECRUITING | — |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | UNKNOWN | PHASE1/PHASE2 |
| NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | RECRUITING | — |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | NOT_YET_RECRUITING | PHASE2 |